<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575834</url>
  </required_header>
  <id_info>
    <org_study_id>20070337</org_study_id>
    <secondary_id>2011-001456-11</secondary_id>
    <nct_id>NCT01575834</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis</brief_title>
  <acronym>FRAME</acronym>
  <official_title>A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with romosozumab is effective in
      preventing fractures in women with postmenopausal osteoporosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2012</start_date>
  <completion_date type="Actual">December 28, 2016</completion_date>
  <primary_completion_date type="Actual">December 14, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With New Vertebral Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With New Vertebral Fracture Through Month 24</measure>
    <time_frame>24 months</time_frame>
    <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Nonvertebral Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Nonvertebral Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Clinical Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Nonvertebral Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Nonvertebral Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hip Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Hip Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Major Osteoporotic Fracture Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12</measure>
    <time_frame>12 Months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12</measure>
    <time_frame>Baseline and Month 12</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24</measure>
    <time_frame>Baseline and Month 24</time_frame>
    <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7180</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered by subcutaneous injection once a month (QM)</description>
    <arm_group_label>Romosozumab</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by subcutaneous injection once a month (QM)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Administered by subcutaneous injection once every 6 months (Q6M)</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Romosozumab</arm_group_label>
    <other_name>Prolia®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Postmenopausal women with osteoporosis, defined as low bone mineral density (BMD T-score
        at the total hip or femoral neck of ≤ -2.50)

        Exclusion Criteria:

          -  BMD T-score of ≤ -3.50 at the total hip or femoral neck

          -  History of hip fracture

          -  Any severe or more than 2 moderate vertebral fractures, as assessed by the central
             imaging based on lateral spine x-rays

          -  Use of agents affecting bone metabolism

          -  History of metabolic or bone disease (except osteoporosis)

          -  Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)

          -  Current hyper- or hypocalcemia

          -  Current, uncontrolled hyper- or hypothyroidism

          -  Current, uncontrolled hyper- or hypoparathyroidism
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mayfield</city>
        <state>Ohio</state>
        <zip>44143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210-8625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1012AAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1430CKE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600DHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Córdoba</state>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425ACG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lommel</city>
        <zip>3920</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>04063-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6M 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lachine</city>
        <state>Quebec</state>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlántico</state>
        <zip>08001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>1</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogota</city>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <zip>580 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klatovy</city>
        <zip>339 38</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 11 - Chodov</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Århus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional</state>
        <zip>10124</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <state>Distrito Nacional</state>
        <zip>10514</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <zip>10605</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pärnu</city>
        <zip>80013</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin (Hellersdorf)</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Görlitz</city>
        <zip>02826</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heinsberg</city>
        <zip>52525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schkeuditz</city>
        <zip>04435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bekescsaba</city>
        <zip>5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heviz</city>
        <zip>8380</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411 005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632 004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anjyo-shi</city>
        <state>Aichi</state>
        <zip>446-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urayasu-shi</city>
        <state>Chiba</state>
        <zip>279-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>910-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>910-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>918-8057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <zip>918-8236</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>814-0111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukutsu-shi</city>
        <state>Fukuoka</state>
        <zip>811-3217</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>806-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>839-0832</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <zip>733-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose-shi</city>
        <state>Hokkaido</state>
        <zip>066-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ishikari-shi</city>
        <state>Hokkaido</state>
        <zip>061-3203</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunagawa-shi</city>
        <state>Hokkaido</state>
        <zip>073-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akashi-shi</city>
        <state>Hyogo</state>
        <zip>674-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kako-gun</city>
        <state>Hyogo</state>
        <zip>675-1115</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toride-shi</city>
        <state>Ibaraki</state>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morioka-shi</city>
        <state>Iwate</state>
        <zip>020-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <zip>760-8538</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirishima-shi</city>
        <state>Kagoshima</state>
        <zip>899-5102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minamikyusyu-shi</city>
        <state>Kagoshima</state>
        <zip>897-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atugi-shi</city>
        <state>Kanagawa</state>
        <zip>243-0122</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>252-5225</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>223-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>223-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>227-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>231-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>860-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>981-3213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiisagata-gun</city>
        <state>Nagano</state>
        <zip>386-0603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-1401</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>390-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <zip>386-0151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ueda-shi</city>
        <state>Nagano</state>
        <zip>386-0405</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bungoono-shi</city>
        <state>Oita</state>
        <zip>879-7125</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>559-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>569-1123</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga-shi</city>
        <state>Saga</state>
        <zip>840-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujimi-shi</city>
        <state>Saitama</state>
        <zip>354-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue-shi</city>
        <state>Shimane</state>
        <zip>699-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujinomiya-shi</city>
        <state>Shizuoka</state>
        <zip>418-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kikugawa-shi</city>
        <state>Shizuoka</state>
        <zip>439-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokushima-Shi</city>
        <state>Tokushima</state>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>192-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiyose-shi</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>157-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>140-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>166-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <zip>166-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kofu-shi</city>
        <state>Yamanashi</state>
        <zip>400-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <zip>49287</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <zip>49456</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>94231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>09310</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vilnius</city>
        <zip>10323</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad Obregon</city>
        <state>Sonora</state>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8022</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grafton, Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dabrowka Dopiewo</city>
        <zip>62-069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pozuelo de Alarcon</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reading</city>
        <zip>RG2 0TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Hong Kong</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-1543. Epub 2016 Sep 18.</citation>
    <PMID>27641143</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17.</citation>
    <PMID>29573473</PMID>
  </reference>
  <reference>
    <citation>Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res. 2018 Aug;33(8):1407-1416. doi: 10.1002/jbmr.3439. Epub 2018 May 11.</citation>
    <PMID>29750828</PMID>
  </reference>
  <reference>
    <citation>Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.</citation>
    <PMID>30508316</PMID>
  </reference>
  <reference>
    <citation>Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z.</citation>
    <PMID>31168657</PMID>
  </reference>
  <reference>
    <citation>Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24.</citation>
    <PMID>31233639</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <results_first_submitted>September 24, 2018</results_first_submitted>
  <results_first_submitted_qc>October 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2018</results_first_posted>
  <disposition_first_submitted>March 7, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2016</disposition_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 222 centers in Europe, Central/Latin America, Asia, North America, and Australia/New Zealand.
The first participant enrolled on 15 March 2012 and the last participant enrolled on 06 December 2013.</recruitment_details>
      <pre_assignment_details>Participants were randomized 1:1 to receive either romosozumab 210 mg or matched placebo for the 12-month, double-blind, placebo-controlled period. Randomization was stratified by age (&lt; 75 years, ≥ 75 years) and prevalent vertebral fracture (yes, no), as determined by site staff at randomization based on local reading of the spine X-ray.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Denosumab</title>
          <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
        <group group_id="P2">
          <title>Romosozumab/Denosumab</title>
          <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3591"/>
                <participants group_id="P2" count="3589"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Double-blind Treatment</title>
              <participants_list>
                <participants group_id="P1" count="3582">Six participants received a dose of romosozumab in error during the double-blind period.</participants>
                <participants group_id="P2" count="3575"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Double-blind Period</title>
              <participants_list>
                <participants group_id="P1" count="3205"/>
                <participants group_id="P2" count="3185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 24-month Study Period</title>
              <participants_list>
                <participants group_id="P1" count="3032"/>
                <participants group_id="P2" count="2994"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2892">Completed 36-month study period</participants>
                <participants group_id="P2" count="2851">Completed 36-month study period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="699"/>
                <participants group_id="P2" count="738"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="352"/>
                <participants group_id="P2" count="390"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative decision</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility Determined</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis set consisted of all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Denosumab</title>
          <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
        <group group_id="B2">
          <title>Romosozumab/Denosumab</title>
          <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3591"/>
            <count group_id="B2" value="3589"/>
            <count group_id="B3" value="7180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" spread="6.9"/>
                    <measurement group_id="B2" value="70.9" spread="7.0"/>
                    <measurement group_id="B3" value="70.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="757"/>
                    <measurement group_id="B2" value="768"/>
                    <measurement group_id="B3" value="1525"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2834"/>
                    <measurement group_id="B2" value="2821"/>
                    <measurement group_id="B3" value="5655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3591"/>
                    <measurement group_id="B2" value="3589"/>
                    <measurement group_id="B3" value="7180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1416"/>
                    <measurement group_id="B2" value="1427"/>
                    <measurement group_id="B3" value="2843"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2175"/>
                    <measurement group_id="B2" value="2162"/>
                    <measurement group_id="B3" value="4337"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2052"/>
                    <measurement group_id="B2" value="2063"/>
                    <measurement group_id="B3" value="4115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="425"/>
                    <measurement group_id="B3" value="866"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian/Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian/Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="901"/>
                    <measurement group_id="B2" value="900"/>
                    <measurement group_id="B3" value="1801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prevalent Vertebral Fracture Strata per Randomization</title>
          <description>Strata per randomization for prevalent fracture were based on local reading of baseline spine radiographs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="409"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3386"/>
                    <measurement group_id="B2" value="3385"/>
                    <measurement group_id="B3" value="6771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age Strata per Randomization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2471"/>
                    <measurement group_id="B2" value="2470"/>
                    <measurement group_id="B3" value="4941"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1120"/>
                    <measurement group_id="B2" value="1119"/>
                    <measurement group_id="B3" value="2239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With New Vertebral Fracture Through Month 12</title>
        <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
        <time_frame>12 Months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 12 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Vertebral Fracture Through Month 12</title>
          <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 12 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3322"/>
                <count group_id="O2" value="3321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With New Vertebral Fracture Through Month 24</title>
        <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
        <time_frame>24 months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Vertebral Fracture Through Month 24</title>
          <description>New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.
The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:
Grade 0 (Normal) = no fracture;
Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);
Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;
Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. Last observation carried forward imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3327"/>
                <count group_id="O2" value="3325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Fracture Through Month 12</title>
        <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set; Last observation carried forward imputation (LOCF) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Fracture Through Month 12</title>
          <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set; Last observation carried forward imputation (LOCF) was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Nonvertebral Fracture Through Month 12</title>
        <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Nonvertebral Fracture Through Month 12</title>
          <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Nonvertebral Fracture Through Month 24</title>
        <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>24 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Nonvertebral Fracture Through Month 24</title>
          <description>A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.057</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Clinical Fracture Through Month 24</title>
        <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>24 Months</time_frame>
        <population>Full analysis set; LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Clinical Fracture Through Month 24</title>
          <description>Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set; LOCF imputation was used</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Nonvertebral Fracture Through Month 12</title>
        <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Nonvertebral Fracture Through Month 12</title>
          <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Nonvertebral Fracture Through Month 24</title>
        <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
        <time_frame>24 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Nonvertebral Fracture Through Month 24</title>
          <description>A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
        <time_frame>12 Months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3322"/>
                <count group_id="O2" value="3321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
        <time_frame>24 Months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3327"/>
                <count group_id="O2" value="3325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hip Fracture Through Month 12</title>
        <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hip Fracture Through Month 12</title>
          <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Hip Fracture Through Month 24</title>
        <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
        <time_frame>24 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Hip Fracture Through Month 24</title>
          <description>Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.</p_value_desc>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</title>
        <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 12</title>
          <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 24</title>
        <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>24 Months</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Major Osteoporotic Fracture Through Month 24</title>
          <description>Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3591"/>
                <count group_id="O2" value="3589"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cox proportional hazards</method>
            <method_desc>Cox proportional hazards model adjusting for age and prevalent vertebral fracture stratification variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>Hazard ratio &lt; 1 favors romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
        <time_frame>12 Months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3322"/>
                <count group_id="O2" value="3321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</title>
        <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
        <time_frame>24 Months</time_frame>
        <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24</title>
          <description>A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.</description>
          <population>Primary efficacy analysis set includes all participants who had a baseline and ≥ 1 postbaseline evaluation of vertebral fracture during the 24 months, including participants with missing baseline Genant scores whose first postbaseline spinal radiograph showed no fracture on the same vertebrae. LOCF imputation was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3327"/>
                <count group_id="O2" value="3325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Based on logistic regression model adjusted for age and prevalent vertebral fracture stratification variables; p-value based on score test.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor romosozumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3148"/>
                <count group_id="O2" value="3151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.1"/>
                    <measurement group_id="O2" value="13.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the lumbar spine was analyzed using an analysis of covariance (ANCOVA) model which included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>12.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.4</ci_lower_limit>
            <ci_upper_limit>12.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="0.1"/>
                    <measurement group_id="O2" value="16.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the lumbar spine was analyzed using an analysis of covariance (ANCOVA) model which included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>11.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.8</ci_lower_limit>
            <ci_upper_limit>11.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3210"/>
                <count group_id="O2" value="3197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="6.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the total hip was analyzed using an ANCOVA model which included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.6</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2918"/>
                <count group_id="O2" value="2903"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.1"/>
                    <measurement group_id="O2" value="8.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the total hip was analyzed using an ANCOVA model which included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 12</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3210"/>
                <count group_id="O2" value="3197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="5.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the femoral neck was analyzed using an ANCOVA model which included included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.9</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24</title>
        <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline and Month 24</time_frame>
        <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Denosumab</title>
            <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab/Denosumab</title>
            <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24</title>
          <description>Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Primary efficacy analysis set for BMD includes all randomized participants who had a baseline and ≥ 1 post-baseline evaluation at or before the time point under consideration in the study period; LOCF imputation was used.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2918"/>
                <count group_id="O2" value="2903"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.1"/>
                    <measurement group_id="O2" value="7.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The treatment comparison of BMD at the femoral neck was analyzed using an ANCOVA model which included included treatment, age and prevalent vertebral fracture stratification variables, and baseline value of the endpoint, machine type and machine type-by-baseline value interaction.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.7</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double-blind treatment period: 12 months; Overall study: 36 months</time_frame>
      <desc>Six participants randomized to placebo received a dose of romosozumab in error during the double-blind period. Therefore, these 6 participants were included in the romosozumab group (ie, as treated) for safety analyses.
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>12-Month Double-blind Period: Placebo</title>
          <description>Participants received placebo subcutaneous injections once a month for 12 months</description>
        </group>
        <group group_id="E2">
          <title>12-Month Double-blind Period: Romosozumab</title>
          <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months.</description>
        </group>
        <group group_id="E3">
          <title>36-Month Study Period: Placebo/Denosumab</title>
          <description>Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
        <group group_id="E4">
          <title>36-Month Study Period: Romosozumab/Denosumab</title>
          <description>Participants received romosozumab 210 mg subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="314" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="733" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="728" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anaemia of chronic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vestibular ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Primary hyperaldosteronism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lens disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Posterior capsule rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Medical device discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholangitis sclerosing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Amoebic colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bacterial tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chikungunya virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Enterobacter bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meningitis pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Phlebitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyelocystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyometra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tick-borne viral encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ureteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Eyelid injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Internal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Postoperative adhesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Postoperative delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Radial head dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Stoma site ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uterine dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactic acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Body mass index increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric pH decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Influenza B virus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hyponatraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypoosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mineral metabolism disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acral lentiginous melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Angiocentric lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of spinal cord</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign pleural neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Benign soft tissue neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Choroid melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Granular cell tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intraocular melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Neoplasm of appendix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Neurofibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paget's disease of nipple</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancoast's tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paranasal sinus benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the hypopharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tracheal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervicogenic headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Internal carotid artery kinking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paralysis recurrent laryngeal nerve</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Post-traumatic headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Personality change due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pseudodementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Schizophreniform disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Transient psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hydrocalyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ureteric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vaginal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vaginal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Choking sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vocal cord cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Granuloma annulare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Immobile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pulmonary resection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2059" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="2019" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="2434" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="2463" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="189" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="191" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="240" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="237" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="439" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="460" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="622" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="651" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="255" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="236" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="263" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="244" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="263" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="230" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="179" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="539" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="484" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="434" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="468" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="663" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="668" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="380" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="373" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="573" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="518" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="201" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="211" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="260" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="263" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="329" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="321" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="278" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="407" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="417" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="158" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="228" subjects_at_risk="3581"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="235" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="270" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="293" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="179" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="189" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="3576"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="3581"/>
                <counts group_id="E3" subjects_affected="411" subjects_at_risk="3576"/>
                <counts group_id="E4" subjects_affected="384" subjects_at_risk="3581"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

